E
SGMO

Ergoteles’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ergoteles’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,243
Closed -$28.9K – 701
2023
Q2 		$28.9K Buy
+22,243
New +$30.4K ﹤0.01% 974
2021
Q3 		– Sell
-16,200
Closed -$194K – 1620
2021
Q2 		$194K Buy
+16,200
New +$183K ﹤0.01% 1292

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ergoteles's SGMO Position: Q3 2023 in Review

Ergoteles sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 22,243 shares — an estimated $28.9K sold.

Ergoteles first reported a position in SGMO in Q2 2021 and held it in 2 quarters. The position peaked at $194K in Q2 2021. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

  • Ergoteles reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 22,243 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $28.9K.
  • Ergoteles first reported a position in SANGAMO THERAPEUTICS INC in Q2 2021 and held it in 2 quarters.
  • Ergoteles's SANGAMO THERAPEUTICS INC position peaked at $194K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.